FarmavitaR+

1. Pricing and Reimbursement Conference Review
(Pricing and Reimbursment/Pricing and Reimbursment)

... that prices of generics in Canada are much higher than in the US and Europe (though there are major differences between provinces - Quebec has the lowest prices). Up to now pharmacies in all Canada ...

2. Biosimilars: Key developments in the regulatory environment
(Reports/Product Report)

... opportunities have been created for generics companies in the biopharmaceutical market, which according to IMS data was valued at $85.9 billion in 2007. Conservative projections estimate that sales of ...

3. New Approaches to Pharma R&D
(Reports/Market Report)

New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming ...

4. Biosimilars expansion in the USA
(Biosimilars/Biosmimilars)

... entered the market to date: hGH, epoetin alpha and filgrastim. Unsurprisingly, all were first launched in Germany, the largest generics market in Europe with a high level of uptake for such products. The ...

5. Generic Benchmarking
(Reports/Market Report)

Generic Benchmarking: Brand Erosion at Patent Expiry Not only is Pharma facing a continued slow down in sales growth in the seven major markets, but erosion of branded drugs by generics follow patent ...

6. The Top 10 Generic Pharmaceutical
(Reports/Company Report)

The Top 10 Generic Pharmaceutical Companies: Positioning, performance and SWOT analyses The global generics market grew at a faster pace than the global pharma market in 2007, with a CAGR of 16.4% ...

7. Optimizing Brand Lifecycle Management
(Reports/Market Report)

Optimizing Brand Lifecycle Management: Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition As competitive pressures from the entry of generics post-patent expiry and new ...

8. Chinese Pharmaceutical Market Overview
(Reports/Market Report)

... Western manufacturers have Chinese based manufacturing plants which can produce generic drugs at low-cost, there is little financial incentive or future prospects for foreign companies in the generics ...

9. Biosimilars: Benchmarking the key players
(Reports/Market Report)

... generics companies, leading biosimilars developers, plus emerging biosimilar developers. Well-established generics companies such as Sandoz and Teva have led the drive into the biosimilars market, ...

10. Benchmarking Patent Expiries
(Reports/Company Report)

... core product patent expires. Competition within the generics market is becoming increasingly fierce with ever more companies entering the market. Generics manufacturers need to be aware of which branded ...

11. Canadian Generics Market
(Reports/Market Report)

An Introduction to the Canadian Generics Market - Key trends and leading companies shaping the market The Canadian pharmaceutical market is the 8th largest globally and as such represents an important ...

12. Biosimilars - Strategic issues
(Reports/Market Report)

... expected they will embrace them after a lag period. Standard incentives used to encourage generics use may not be applicable to biosimilars distributed in hospitals and alternative approaches need to be ...

13. Key trends
(Reports/Market Report)

Key trends and events in the 7 major markets The generics market is growing, driven by rising healthcare costs and fed by a steady stream of patent expiries. Levels of generic uptake vary widely ...

14. Sales Outlook for Big Pharma
(Reports/Company Report)

... M&A with other Big Pharma companies, biotech, Mid Pharma CNS players and/or generics manufacturers and acquisitional moves outside of 'pharma space' to increase presence in medical devices, diagnostics ...

15. Growth Opportunities in Generics
(Reports/Market Report)

Future Growth Opportunities in Generics: Impact of consolidation on market and competitive dynamics The number of commercially lucrative drugs coming off patent has catalyzed the growth of the ...

16. The Indian Pharmaceutical Market
(Reports/Market Report)

The Indian Pharmaceutical Market to 2011: Competitive dynamics and major players Traditionally, the Indian pharmaceutical industry has been characterized by a core competency in generics’ ...

17. FDA Improves Generic Drug Access
(Regulatory Affairs/North America)

... implement these important legislative reforms that speed the approval of generics. The agency will also issue a Federal Register notice revoking a regulation the agency had issued last year that limited ...

18. IMS Global Report
(Reports/Market Report)

... costs. In Europe, their tactics include price freezes, across-the-board cost cuts, incentives for using generics and scrutiny of comparative effectiveness between drugs. Says Aitken, “Payer ...

19. Atorvastatin
(Pharmaceutical product/Pharmaceutical product)

... the interplay between brands and generics: - “…some of these generics manufacturers are seeking to upset this delicate balance by playing “litigation lotto,” attacking our intellectual property in court ...

20. Biosimilars IP
(Biosimilars/Biosmimilars)

... method of registration for generics. Before that, there had been virtually no generics market in the USA due to the massive barriers to entry, which had made the process too difficult for cheap copies ...